EP3000457A1 - Poche de stockage de solution therapeutique - Google Patents

Poche de stockage de solution therapeutique Download PDF

Info

Publication number
EP3000457A1
EP3000457A1 EP15188993.8A EP15188993A EP3000457A1 EP 3000457 A1 EP3000457 A1 EP 3000457A1 EP 15188993 A EP15188993 A EP 15188993A EP 3000457 A1 EP3000457 A1 EP 3000457A1
Authority
EP
European Patent Office
Prior art keywords
membrane
solution
pocket
storage bag
compartment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15188993.8A
Other languages
German (de)
English (en)
French (fr)
Inventor
Priscille Paruit
Brigitte Chaumeton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42062393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3000457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LFB SA filed Critical LFB SA
Publication of EP3000457A1 publication Critical patent/EP3000457A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D29/00—Sacks or like containers made of fabrics; Flexible containers of open-work, e.g. net-like construction
    • B65D29/02—Sacks with laminated or multiple walls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1462—Containers with provisions for hanging, e.g. integral adaptations of the container
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/10—Bar codes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/30—Printed labels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00—Decoration means, markings, information elements, contents indicators
    • B65D2203/02—Labels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D33/00—Details of, or accessories for, sacks or bags
    • B65D33/004—Information or decoration elements, e.g. level indicators, detachable tabs or coupons

Definitions

  • the present invention relates to a therapeutic solution storage bag and a method of manufacturing such a storage bag.
  • therapeutic solution any type of product in liquid form used for a therapeutic purpose.
  • blood components in liquid form for example blood plasma, platelets, or a packed cell.
  • blood plasma derivatives for example albumin or an immunoglobulin.
  • It can also be medication solutions, or even nutritional solutions.
  • glucose solution for example at 5%, G5, or else saline solutions, especially isotonic solutions or a Ringer's solution.
  • Storage bags like glass bottles, are subject to very demanding regulations, particularly with regard to their manufacture and traceability.
  • the pockets must have an inscription providing information about the solution, safety elements such as, the name of the manufacturer, the expiry date, the lot number, the recipient or the name of the patient, including traceability of the solution.
  • the pouches are usually packaged and sent to hospitals or to any recipient who can administer the solution to a patient. The patient can himself be a recipient and administer the solution.
  • the bags currently on the market have an inscription carried directly on a membrane delimiting a receiving compartment of the solution, as is the case of the Flexbumin ® flexible pouch, flexible pouch containing human albumin, manufactured and marketed, particularly in Sweden, by Baxter.
  • the inscription can also be worn by gluing a label on which it was previously written, printed and / or stamped, or by gluing a blank label on which one writes and / or stamps thereafter.
  • the inscription can also be worn directly on the membrane by handwriting typically with a pen or pen or ink pad. This is particularly the case when the bag is used to administer an infusion to a patient. It may be that during the course of administration the contents of the bag are modified, for example by the addition of a drug, and that the nursing staff then wear a marker indicating the modification in question. quantity to be administered or the administration time to be respected.
  • Flexible storage pockets are described in the patent application WO 02/072429 and the patent US 4,654,240 from Baxter.
  • the patent application WO 02/072429 discloses a flexible polymer pouch for storing a solution of peptides and / or proteins, as well as a method of introducing such a solution into a flexible polymer container. The manner of carrying an inscription on the storage bag is not mentioned in this document.
  • the patent US 4,654,240 discloses a laminated film material for a flexible pouch capable of storing a product to be maintained and extracted under sterile conditions. The bag is optionally steam sterilized. The way of carrying an inscription on the storage pocket is not mentioned in this document either.
  • a solution to reduce the risk of contamination in the case where the inscription is carried on the membrane is to use a particular ink whose molecules pass through the membrane more difficult.
  • such an ink is expensive.
  • this solution does not sufficiently reduce the risk of contamination because ink molecules continue to cross the membrane, and because the membrane can still be damaged.
  • this solution does not respond to the risk of contamination related to the inscription carried by sticking a label. There is therefore a need to enhance the safety of the batches of therapeutic solution.
  • the Applicant has surprisingly developed by the present invention a storage bag of a therapeutic solution, providing an improvement in the safety of the therapeutic solution, and allowing to carry an inscription while reducing the risk of contamination. .
  • the invention proposes a therapeutic solution storage pouch comprising at least one solution-receiving compartment delimited by a membrane.
  • the bag further comprises at least one appendage in the extension of the membrane and having a registration area.
  • the method further comprises a step of irradiating the storage bag before step (i) filling.
  • the invention relates to a therapeutic solution storage bag.
  • the pocket comprises at least one receiving compartment of the solution.
  • the pocket also includes a membrane, the compartment being the space delimited by the membrane.
  • the pocket also comprises at least one appendix in the extension of the membrane and having a registration area.
  • the membrane may consist of a single piece folded and / or welded so as to define the compartment.
  • the membrane may also consist of an assembly of several parts welded together so as to define the compartment.
  • the compartment allows the reception of a volume of solution for its storage.
  • the registration area allows for an inscription providing information relating to the pocket.
  • This information relates in a non-limiting manner to one or more of the following: the content of the solution, the producer of the solution and its logo, the seller of the solution, the concentration of the solution, information on the hospital or the institution or the recipient, the name of the patient.
  • the information can be coded by presenting for example in the form of a barcode or datamatrix (matrix consisting of juxtaposed points or squares, equivalent to the barcode in two dimensions).
  • the inscription may be carried, in a non-limiting manner, by writing by hand with ink on the appendix, by gluing or stapling a label on which was previously printed, handwritten, or stamped, or by gluing or stapling a blank label on which the inscription is subsequently handwritten or stamped.
  • the registration area is on the appendage in the extension of the membrane, it is possible to wear an inscription on the pocket with a reduced risk of contamination. Indeed, carrying an inscription on an area of an appendage in the prolongation of the membrane and not directly on the membrane in contact with the solution reduces the risk of deterioration of the membrane and migration of contaminating molecules towards the membrane. compartment.
  • mirage refers to a visual inspection operation on containers intended to detect any contamination or other defects, such as particles, filling defects, pieces of plastic.
  • FIG 1 has a view of a storage pocket 10 according to a preferred embodiment of the invention.
  • the pocket 10 comprises a solution receiving compartment 11 delimited by a membrane 12 .
  • the pocket 10 also comprises an appendage 13 in the extension of the membrane 12 .
  • the appendix 13 protrudes from the membrane 12 , but not necessarily in the axis or in the plane of the membrane 12 .
  • Appendix 13 has an inscription area 14 , which is separated from the membrane 12 into a separate area.
  • An inscription 15 providing information on the bag can be worn with a reduced risk of contamination.
  • the membrane 12 is transparent. This makes it possible to examine visually or by any other equivalent means a solution stored in the pocket 10 . Indeed, carrying an inscription on an area of an appendage in the extension of a transparent membrane and not directly on the membrane improves the effectiveness of the mirage, especially at the time of filling, because the membrane is blank of any impression, but also at the moment of use by hospital staff to check the clarity of the solution to be infused.
  • precautionary measures There are standards in the medical field that require care providers to take certain precautionary measures before administering a therapeutic solution to a patient.
  • An example of such a precautionary measure is the visual inspection operation which consists of several steps allowing the caregiver to visually verify that no deposit has formed or that no impurity is present in a solution. therapeutic before an infusion.
  • the transparency of the membrane 12 thus allows the caregiver to take the precautionary measures requiring visual inspection of the solution stored in the pocket, such as in particular the verification of the color of the therapeutic solution or the presence of bacterial or particulate contamination in the patient. within the therapeutic solution to infuse 10 .
  • the storage pockets on the market have an inscription on the membrane.
  • an inscription on the membrane is an inconvenience for the nursing staff when it wishes to take the precautionary measures mentioned above.
  • An inscription on the membrane is also an inconvenience when the caregiver wishes to check the volume of solution contained in the compartment 11 , for example to verify that an infusion is proceeding correctly.
  • the presence of this inscription on the membrane is a hindrance during the operation of mirage therapeutic solutions.
  • the inscription zone 14 is separated from the transparent membrane 12 . No registration thus hinders the eye, which facilitates and consequently speeds up the work of the nursing staff. The facilitation of the work of the nursing staff is of great importance especially in emergency care.
  • the membrane 12 is not transparent, but rather opaque in order to protect the solution from light irradiation. This can be the case when the solution stored in the bag 10 is not directly administered, but taken for example by means of a syringe before being administered. In this case, the precautionary measures mentioned above can be taken after taking the solution from the syringe. It is also possible that the solution is administered from the bag 10 in this case of the opaque membrane.
  • One of the embodiments of the invention uses a surface ratio of the appendix / pocket storage area of between 0.15 and 0.40, preferably between 0.20 and 0.35, in particular between 0.25 and 0. , In particular equal to 0.27.
  • the membrane 12 of the figure 1 comprises an orifice 16 .
  • the orifice 16 allows the injection into the compartment 11 of a solution for storage.
  • the orifice 16 also allows the flow of a solution stored out of the compartment 11 for its administration by infusion to a patient.
  • the orifice 16 is connected to a conduit, not shown, administering the solution to a patient.
  • the conduit connects the compartment 11 to a vein of the patient.
  • the orifice 16 may also be used as an access route for taking a certain amount of solution using a syringe or other sampling tool.
  • the orifice 16 may also be used as an access route for the injection of a given quantity of a medicament, for example for the treatment of cancer patients, for whom a solution of active principle is injected. in the pocket, possibly after reconstitution by the medical staff.
  • the membrane may also include several orifices.
  • the membrane may comprise two orifices: a first orifice for injecting the solution into the compartment for its storage, and a second orifice for the flow of the solution out of the compartment for its administration to a patient.
  • a pocket comprising a plurality of orifices makes it possible to add elements to a solution stored in the pocket via the first orifice at the same time as the solution flows through the second orifice during the infusion.
  • the orifice 16 is advantageously located in an area opposite the appendix 13 with respect to the compartment 11 .
  • the appendix 13 may be provided with an attachment member 17 , as is the case in the embodiment of the figure 1 .
  • the fastening member 17 consists of a hole passing through the appendix 13 .
  • This configuration is however not limiting. Indeed, a different number of holes can be made.
  • other types of attachment members such as a magnet, a hook protruding from the appendix 13 or an adhesive can be used.
  • it is possible to have a pre-cut hook in Appendix 13 and can be unfolded to allow snapping.
  • the fastening member 17 makes it possible to suspend the pocket at a support preferably located at a height.
  • the orifice 16 being located in an area opposite the appendage 13 with respect to compartment 11, the suspension of the bag 10 by the coupling member 17 allows flow of the solution from the compartment 11 through port 16 under the effect of gravity.
  • the bag 10 can thus be suspended over a patient and be used as an infusion bag.
  • the term "zone opposite to the appendix to the compartment" means the zone of the membrane 12 the lowest when the bag is suspended by a fastening member 17 of Appendix 13 .
  • the orifice or the orifices intended for the flow of the solution out of the compartment 11 are situated in an area opposite to the appendix 13 with respect to the compartment 11 , which ensures flow of the solution under the effect of gravity.
  • the flow of the solution is by means of a pump, or even by compression of the compartment 11 , especially in the infusion assisted infusion mode.
  • the orifice 16 may as well be located in an opposite zone to the appendix 13 with respect to the compartment 11 as in another zone, the gravity being no longer necessary to ensure the flow of the solution.
  • the orifice 16 is provided with a closure member 18 .
  • This closure member makes it possible to prevent an unwanted flow of the solution.
  • the closure member 18 can be used for the closure member 18 .
  • the fixed portion 19 may be closed by the removable portion 20 , or by another element, although it has been previously removed using for example a screw mechanism.
  • This configuration makes it possible to close the orifice 16 despite a first beginning of flow of the solution. This configuration is of interest for example when it is desired to temporarily interrupt an infusion.
  • the membrane 12 is preferably made of a flexible material. It is advantageously a plastic material. PVC, polyethylene, polypropylene or any other material commonly used for producing flexible bags can be used. The thickness of the films is classic.
  • the membrane is made from polypropylene.
  • the flexibility of the pocket 10 allows easier storage of the pocket 10 , a simpler waste disposal, as well as greater ease of use compared to rigid bottles. Moreover, the membrane being made of a flexible material, it is unbreakable. This avoids the problems of decontamination related to the use of glass vials.
  • the membrane 12 may also consist of multilayer films, in particular three-layer films, the materials constituting the various layers having their own functions, for example a barrier (for example an oxygen barrier or an infusion product), a support, a binder between two layers , etc.
  • a barrier for example an oxygen barrier or an infusion product
  • a use of several layers makes it possible to further reduce the risk of contamination and to increase the resistance capacities of the membrane 12 , in particular to physical stresses and to beta-ray irradiations.
  • a use of three layers makes it possible to compromise between an increase in the resistance and the preservation of the transparency of the membrane 12 .
  • the bag may also be placed in a removable outer envelope preferably waterproof.
  • This outer shell has the advantage of constituting a physical barrier for the loss of water.
  • this outer envelope if it is opaque, protects the solution from denaturations that could be induced by light.
  • Such an outer envelope is particularly advantageous in the case where the solution stored in the bag 10 is albumin or an immunoglobulin for example, particularly sensitive to light.
  • the immunoglobulin can be manufactured according to the method described in the documents FR-2824568-A1 and FR-2895263-A1 . It may be an intravenous immunoglobulin G (IVIG).
  • IVIG intravenous immunoglobulin G
  • the outer casing may also consist of multilayer films, in particular three-layer films, the constituent materials of the different layers having their own functions, for example that of blocking the light, or that of ensuring a seal.
  • the outer shell can be made of aluminum or plastic or a mixture of both.
  • the outer casing may be thermoformed around the storage bag 10 .
  • the outer envelope consists of a multilayer film containing an aluminum layer surrounded on both sides by a layer of plastic, for example polypropylene, which makes it gives special resistance to shocks, and is a barrier to light.
  • the outer envelope consists of a polyethylene layer, an aluminum layer and a polypropylene layer.
  • a storage bag 10 according to the invention containing a therapeutic solution is packaged in the outer envelope and then sent to a recipient. Before the use of the pocket 10 , the recipient removes the envelope external. Thus, the envelope is an additional protection until it is removed, that is to say until the use of the pocket 10.
  • the compartment 11 has a capacity of maximum capacity of between one milliliter and one liter, advantageously a capacity of maximum capacity of between 5 and 500 milliliters, advantageously between 10 and 500 milliliters, and still more advantageously between 20 and 200 milliliters, advantageously 50 and 100 milliliters.
  • the pouch has a capacity of up to 100 milliliters.
  • the invention is all the more interesting that the volume of the compartment 11 is small.
  • the smaller the volume of the compartment 11 the smaller the surface of the membrane 12 , and the more an inscription on the membrane 12 constitutes an inconvenience.
  • the pocket 10 comprises a weld separating the membrane 12 from the appendix 13 .
  • the weld gives a flexibility to the appendix 13 relative to the compartment 11 . This flexibility is useful especially in the case where several pockets storing a solution are stored in a storage box. Since the inscription 15 is on an inscription area 14 of Appendix 13 , it is possible to identify a pocket without removing it from the box. The work of the nursing staff is thus facilitated.
  • the bag comprises a plurality of solution receiving compartments.
  • a membrane delimits the compartments, and as in the embodiment of the figure 1 , an appendage is in the extension (projecting) of the membrane.
  • several appendices may be in the extension of the membrane, one after the other or next to each other superimposed on each other. This allows to carry several inscriptions on the pocket. This allows for example to carry an inscription per compartment when the pocket comprises several compartments.
  • the bag may be provided with a mixer ensuring a mixture of the contents of the different compartments, the mixture then flowing through the orifice.
  • the bag may also be provided with an orifice per compartment, a mixture then being provided by a mixer outside the bag.
  • the new flexible pouch according to the invention is manufactured by any conventional method of manufacturing flexible pouches.
  • the compartment 11 is prepared by welding according to a predefined scheme, by welding a folded membrane on itself or two separate films. A cover is provided during the welding, conventionally.
  • the welding can also be done in a conventional manner, by heat-sealing or ultrasound.
  • the appendage in the extension (projecting) can be attached by welding on an already existing pocket, or on the contrary be obtained directly during manufacture.
  • the folded membrane on itself can be continued to form the appendix; it is also possible that the two films are welded together to form the appendix, or that only one of the films is extended to form the appendix.
  • the pouch comprises a weld 21 between separating the membrane of the appendix.
  • the method may include a step of irradiating the storage bag prior to step (i) of filling to sterilize the bag.
  • the irradiation is by beta 25 kilograys.
  • the method may comprise an intermediate step of pasteurization and / or incubation of the storage bag containing the therapeutic solution, after the step (ii) of capping and before the step (iii) of candling of the storage bag.
  • the method comprises an intermediate step of pasteurization and incubation between steps (ii) and (iii).
  • the tested pouches conform to the figure 1 . These are pockets previously sterilized by ⁇ -irradiation, at 25 kGy.
  • the membrane 12 is each time transparent, comprises an orifice 16 provided with a twist-off, and is a multilayer membrane consisting of three layers of polypropylene.
  • the pouch 12 also comprises an outer casing made of a multilayer film containing an aluminum layer surrounded on either side by a plastic layer.
  • the aluminum layer has a thickness of 8 ⁇ m.
  • the layers surrounding the aluminum layer are polypropylene terephthalate and polypropylene and have a thickness of 12 microns and 75 microns respectively.
  • the outer envelope also called “overpouch” below and in the figures) is thus waterproof and opaque.
  • the outer envelope has a width of substantially 160 mm and a length of substantially 270 mm.
  • the compartment 11 has a capacity of maximum capacity substantially equal to 100 milliliters. In both cases also, pre-prints information on labels, and for each pocket, it then sticks a label on the registration area (14) of the appendix (13) in the extension of the membrane (12), and another label is glued to the outer envelope.
  • the albumin volume is uniform and is substantially equal to 50 or 100 ml depending on the batch (hereinafter referred to as "lot in 50/100 ml presentation" depending on the capacity of the pockets of the lot in question).
  • the analyzes can be classified according to three categories according to their characterization: qualitative, microbiological or functional.
  • the qualitative characterization of the bags focuses on the appearance of the solution (color, degree of opalescence), pH, osmolality, concentration of polymers, aggregates, enzymatic degradation products, sodium , to the potential adsorption of the stabilizer sodium caprylate, to the study of the migration of the highly toxic component of the overpouch aluminum, to the study of the prekallikrein activator, to the observation of the presence of water between the membrane and the overpouch, to the extent of the extractable volume and the weight of the pocket to highlight a possible loss of water during storage.
  • Microbiological characterization focuses on sterility.
  • the functional characterization focuses on the total protein content (active ingredient content).
  • Table I groups the different analyzes and provides for each the method used and the acceptance criterion applied. ⁇ b> ⁇ u> Table I: Analysis, Method and Application Criteria Applied ⁇ / u> ⁇ /b> Analysis Method Criteria of acceptance Aspect of the solution - Color - Degree of opalescence Ph.Eur 2.2.2 Ph.Eur 2.2.1 Virtually colorless, yellow (J, JB ⁇ JV3) Clear pH Ph.Eur 2.2.3 6.7-7.3 Osmolality (mosmol / kg) Ph.Eur 2.2.35 200-300 Total protein (g / l) Ph.Eur 2.5.33 method 5 190-210 Polymers and aggregates (%) Ph.Eur 2.2.29 ⁇ 5 Sodium caprylate (mg / g protein) Ph.Eur 2.2.28 12.80 - 16.80 Sodium (mmol / l) Ph.Eur 2.2.22 114-126 Degradation Products (%) Ph.Eur 2.2.29 ⁇ 5 Extractable volume Ph.Eur 2.9.17
  • Table II presents the results for a batch in 50ml presentation subjected to the set of conditions ECE 1, the batch being representative.
  • the statistical analysis of the results shows the absence of a change in the total protein content as a function of the storage time for all the batches, except for one lot in the 100 ml presentation, for which a decrease in the total protein content is observed over time (existence of a linear regression, p ⁇ 0.05). But this decrease has no impact on the quality of the product, given the conformity of the results obtained at each deadline.
  • Table III presents the results for a batch in 100ml presentation subjected to the set of conditions ECE 2, the batch being representative.
  • the statistical analysis of the results shows the absence of a change in the total protein content as a function of the storage time for all the batches, except for one batch in 50 ml presentation and one batch. in presentation 100 ml, for which a decrease in the total protein content is observed over time (existence of a linear regression, p ⁇ 0.05). But this decrease has no impact on the quality of the product, given the conformity of the results obtained at each deadline.
  • Example 2 Study of the stability of IgNG (normal immunoglobulin G) 5% stored in test pouches
  • Example 1 The notations of Example 1 are repeated.
  • ECE 1 normal immunoglobulin G
  • ECE 2 ie 40 ° C ⁇ 2 ° C RH ⁇ 25%).
  • glass vials are filled with the same quantity and then stored under the same conditions for reference.
  • the analyzes carried out are primarily aimed at verifying the stability of 5% IgNG in the pockets and a possible loss of water during storage, resulting from the diffusion of water through the multilayer membrane of the pocket.
  • the analyzes are carried out at T0 and after storage for 1 month and 3 months, at 25 ° C. and 40 ° C.
  • the methods used are those recommended by the European Pharmacopoeia with regard to the appearance of the solution (degree of opalescence and color), pH, osmolality, total protein content (HPSEC, Anti-Hbs activity, AAC ).
  • the fragment assay ( ⁇ 3%), the evaluation of the presence of visible and sub-visible particles, and the tween 80 assay are also performed.
  • the aspect of the pocket (flexibility of the membrane, transparency, sealing of the welds, presence of water between membrane and overflow) is also followed.
  • the extractables and relargables are dosed, according to the "guideline on plastic immediate packaging materials" (CPMP / QWP / 4359/03).
  • the extractables study is carried out with four extraction matrices (EPPI, NaOH, HCl and ethanol), at 100 ° C., for 5 hours. Only antioxidants are sought. This study being carried out on non-irradiated bags, a study on ⁇ pockets radiated at 50 kGy is also conducted. EPPI is used as an extraction medium in this study.
  • the substances released from the pockets of IgNG stored for 3 months at 25 ° C and 40 ° C are assayed, in view of the results of the study extractables.
  • the analyzes are of a semi-quantitative nature, which means that the assays have not been validated beforehand. For techniques requiring extraction (in dichloromethane) of potentially salted organic compounds (GC / MS and PTVGC / MS), the extraction yield may not be total and the values underestimated. On the other hand, by this semi-quantitative analysis, the response factor of the detected species is assumed equal to that of the internal standard, which is not always accurate.
  • Tables IV and V present the results of the stability study of the bags under the conditions ECE 1 and ECE 2 respectively, with each time the result of the references (glass bottles).
  • the results show that IgNG is not destabilized in the pockets after 3 months at 25 ° C and 40 ° C, compared to storage in a glass bottle.
  • the increase in the polymer and fragment content at 40 ° C. is comparable in the pockets and the glass bottles.
  • the anti-HBS activity decreases in the same proportions in the pockets and glass vials.
  • There is no clear evolution of the AAC the different results being related to the variability of the test.
  • the use of an all-aluminum overpouch proved effective in preventing water loss. Ig concentration and osmolality do not increase after 3 months of pocket storage with overpouch.
  • the main entities detected are Irganox 1076, Irganox 1010, Irganox 1330, Irgafos 168 and Irgafos 168 oxidized at concentrations below the limit of 1 ppm set by the Pharmacopoeia. European, for extractions in aqueous medium and at very low concentrations for extraction in ethanol. In the case of the ⁇ -radiated pockets, volatile compounds by HS-GC / MS and semi-volatile by GC / MS, conventionally known as degradation products or solvents of the polymers have been identified.
  • Tables VI and VII below provide the evolution of the content of volatile compounds detected in pockets filled with 5% IgNG after storage for three months at 25 ° C. and 40 ° C. respectively. The values are expressed in ppb. ⁇ b> ⁇ u> Table VI: Evolution of the content of volatile compounds at 25 ° C ⁇ / u> ⁇ /b> Time (months) 0 1 3 isobutylene 12 7 9 Cylcohexane 43 24 17 Ethyl acetate 0 170 180 Time (months) 0 1 3 isobutylene 12 8 12 Cylcohexane 43 17 14 Ethyl acetate 0 210 190 Acetone 0 0 5 tert-butanol 0 0 6
  • the values detected are of the order of ppb and close to the detection limit of the method (5 ppb); the differences between the maturities are not significant.
  • These are degradation products of polymers, identified in the study of extractables and solvents of the polymers used in the production of the bags. Only the evolution of the ethyl acetate content is significant. While this solvent is not initially detected, it is released after 1 month of storage, at concentrations that remain low.
  • Tables VIII and IX below provide the evolution of the content of volatile compounds detected in pockets filled with 5% IgNG, after storage for three months, at 25 ° C and 40 ° C respectively. The values are expressed in ppb. ⁇ b> ⁇ u> Table VIII: Evolution of the content of semi-volatile compounds at 25 ° C ⁇ / u> ⁇ /b> Time (months) 0 1 3 2,4-di-tert-Butylphenol 25 240 200 Time (months) 0 1 3 2,4-di-tert-Butylphenol, 25 130 110 Benzyl alcohol, 0 0 11 Ethylhexanoic acid, 0 14 15 Unknown, 0 0 18 bislactone, 0 44 110 Tert-butyl-oxaspirodecadienedione, 0 20 40 (tert-butyl-hydroxyphenyl) propionic acid, 0 19 34

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
EP15188993.8A 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique Withdrawn EP3000457A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0904031A FR2949195B1 (fr) 2009-08-24 2009-08-24 Poche de stockage de solution therapeutique
EP10752431.6A EP2470147B1 (fr) 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP10752431.6A Division EP2470147B1 (fr) 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique

Publications (1)

Publication Number Publication Date
EP3000457A1 true EP3000457A1 (fr) 2016-03-30

Family

ID=42062393

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15188993.8A Withdrawn EP3000457A1 (fr) 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique
EP10752431.6A Not-in-force EP2470147B1 (fr) 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10752431.6A Not-in-force EP2470147B1 (fr) 2009-08-24 2010-08-23 Poche de stockage de solution therapeutique

Country Status (13)

Country Link
US (2) US9468585B2 (da)
EP (2) EP3000457A1 (da)
KR (1) KR20120048693A (da)
CN (1) CN102548522A (da)
AU (1) AU2010288193A1 (da)
BR (1) BR112012004006A2 (da)
CA (1) CA2771736A1 (da)
DK (1) DK2470147T3 (da)
ES (1) ES2558529T3 (da)
FR (1) FR2949195B1 (da)
IL (1) IL218133A0 (da)
PL (1) PL2470147T3 (da)
WO (1) WO2011024112A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
GR20120100242A (el) * 2012-05-04 2014-01-02 Micrel Ιατρικα Μηχανηματα Α.Ε., Αντλια και προγεμισμενος ασκος/σετ αναλγησιας
WO2014099513A1 (en) * 2012-12-19 2014-06-26 Advanced Preservations Technologies, Llc Device for preserving blood products in a gas medium under pressure
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
EP3047833B1 (en) 2015-01-26 2017-03-01 Fresenius Kabi Deutschland GmbH Container closure system
NO20150142A1 (en) * 2015-01-30 2016-08-01 Pronova Biopharma Norge As Enteral feeding device
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
JP2020083426A (ja) * 2018-11-29 2020-06-04 花王株式会社 シート材容器
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1348898A (fr) * 1963-02-27 1964-01-10 Abbott Lab Sac pour contenir un liquide destiné à être administré à un patient
US4654240A (en) 1984-09-28 1987-03-31 Baxter Travenol Laboratories, Inc. Laminate film for flexible containers
WO1992019284A1 (en) * 1991-05-08 1992-11-12 Baxter International Inc. Container for irradiation of blood products
US5514106A (en) * 1994-12-20 1996-05-07 Baxter International Inc. Bag including an identification system indicative of treatment of the bag
WO1997042897A1 (en) * 1996-05-13 1997-11-20 B. Braun Medical Flexible, multiple-compartment drug container and method of making and using same
US5896989A (en) * 1998-02-20 1999-04-27 Bracco Research Usa Flexible medical container packaging
WO2002072429A1 (en) 2001-03-12 2002-09-19 Baxter International, Inc. Albumin in a flexible polymeric container
FR2824568A1 (fr) 2001-05-11 2002-11-15 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CN2882604Y (zh) * 2006-03-31 2007-03-28 湖南千山制药机械股份有限公司 带独立标签及装药接口的输液袋
FR2895263A1 (fr) 2005-12-26 2007-06-29 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2693189A (en) * 1950-12-15 1954-11-02 Abbott Lab Venoclysis equipment
US2895475A (en) * 1956-12-03 1959-07-21 Everett L Cole Container for collecting, storing and dispensing biological fluids
FR1348398A (fr) 1962-09-11 1964-01-10 Carves Simon Ltd Perfectionnement à l'aération et à la séparation des liquides
US3905477A (en) * 1972-03-14 1975-09-16 Union Carbide Corp Tamperproof pouch label
ZA73589B (en) * 1972-03-14 1973-10-31 Union Carbide Corp Tamperproof puch label
US3915212A (en) * 1973-12-10 1975-10-28 Abbott Lab Flexible medical fluid container having a combined fill and administration port and reinforced hanger
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
US3994412A (en) * 1976-03-11 1976-11-30 Abbott Laboratories Tamperproof breakaway port
US4201208A (en) * 1977-11-30 1980-05-06 Abbott Laboratories Sterile connecting device
US5066290A (en) * 1986-02-07 1991-11-19 Baxter International Inc. Sterilizable multi-layer plastic materials for medical containers and the like
EP0605705B1 (en) 1992-07-29 1997-05-21 Baxter International Inc. Pharmaceutical containers and medical devices with hydrophilic protein-compatible surfaces
US5390796A (en) * 1992-10-02 1995-02-21 Kerfoot, Jr.; Franklin W. Envelope apparatus for dispensing medications from drug files
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
ATE209063T1 (de) * 1994-05-11 2001-12-15 Baxter Int Blutsammelsystem
US5910138A (en) * 1996-05-13 1999-06-08 B. Braun Medical, Inc. Flexible medical container with selectively enlargeable compartments and method for making same
US5984912A (en) 1997-07-25 1999-11-16 Brocco Diagnostics, Inc. Collapsible medical bag for the containment and delivery of diagnostic contrast media and parenteral drug formulations
KR100381326B1 (ko) * 1997-10-27 2003-04-23 가부시키가이샤 오츠까 세이야꾸 고죠 안관류·세정액 백포장체
US6183460B1 (en) * 1998-01-22 2001-02-06 Baxter International Inc. Multi-use solution container having flaps
TW367247B (en) * 1998-02-03 1999-08-21 Otsuka Pharma Co Ltd Storage container for Vitamin D solution and transfusion container
US20020056989A1 (en) 1998-04-02 2002-05-16 Lewis-Leander Medication i.v. warning label
US6267745B1 (en) 1998-05-21 2001-07-31 Baxter International Inc. Confined air tube and methods for handling air in closed blood processing systems
US6200300B1 (en) * 1998-11-18 2001-03-13 David S. Smith Packaging Limited Hangable container
JP3607103B2 (ja) * 1998-12-14 2005-01-05 株式会社大塚製薬工場 多層フィルムおよび容器
US7025877B1 (en) * 1999-06-03 2006-04-11 Baxter International Inc. Processing set for processing and treating a biological fluid
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
GB2358386B (en) * 1999-11-25 2004-04-07 Zeal Medical Flexible storage containers for blood platelets
US6199698B1 (en) * 1999-12-03 2001-03-13 Alusuisse Technology & Management, Ltd. Pharmaceutical packaging with separation means
US6613036B1 (en) * 2000-02-01 2003-09-02 Abbott Laboratories Light-protective container assembly and method of making same
US7243689B2 (en) * 2000-02-11 2007-07-17 Medical Instill Technologies, Inc. Device with needle penetrable and laser resealable portion and related method
GB2359386B (en) 2000-02-16 2004-08-04 Data Connection Ltd Replicated control block handles for fault-tolerant computer systems
US20010047162A1 (en) * 2000-02-17 2001-11-29 Yasumi Yugari Injection kit and injection device
US6328082B1 (en) * 2000-03-07 2001-12-11 Bbtresor Inc. Disposable sterile bag, e.g. for breast milk
US6723076B1 (en) * 2000-03-24 2004-04-20 Michael Strobel Animal drug delivery device
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
CA2444590C (en) 2001-04-18 2009-12-01 Robert L. Mcginnis Stabilized hemoglobin solutions
US6845883B2 (en) * 2001-10-18 2005-01-25 Kenneth H. Pieri Toothpaste dispenser
JP2003135563A (ja) 2001-11-02 2003-05-13 Nipro Corp 小型の袋状薬剤容器
US8839538B2 (en) * 2001-11-02 2014-09-23 Quality Assured Enterprises, Inc. Tube container with an integral accessory panel
US6786515B2 (en) * 2001-11-02 2004-09-07 Quality Assured Enterprises, Inc. Tube container with an integral panel for carrying a label
EP1596967A4 (en) * 2003-02-13 2006-06-14 Ilc Dover Inc FLEXIBLE DISPOSABLE CONTAINER
US20050085785A1 (en) * 2003-10-17 2005-04-21 Sherwin Shang High impact strength film and non-pvc containing container and pouch and overpouch
US7264582B2 (en) * 2004-03-11 2007-09-04 2004Adploy Limited Partnership Pouch containers having advertising media and methods for their dissemination
DE202004012986U1 (de) * 2004-08-19 2004-10-14 Anton Debatin GmbH Werk für werbende Verpackung Sicherheitsbeutel
FR2874816B1 (fr) * 2004-09-08 2006-12-08 Guerbet Sa Ensemble de stockage pour produits de contraste
US7297384B2 (en) 2004-12-07 2007-11-20 Shawn Kelly Crowley Metallized heat resistant material with thermal barrier
ATE475607T1 (de) * 2004-12-20 2010-08-15 Bharat Petroleum Corp Ltd Form zum verpacken von bitumen
US8338093B2 (en) 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
US8354249B2 (en) 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
CN101394869A (zh) * 2006-02-28 2009-03-25 诺沃-诺迪斯克有限公司 用于包装材料灭菌的方法和设备
CN101400315B (zh) * 2006-03-09 2013-03-27 3M创新有限公司 材料分配器件
JP2007236757A (ja) * 2006-03-10 2007-09-20 Hosokawa Yoko Co Ltd 輸液バッグ包装体および包装袋
BRPI0711586A2 (pt) * 2006-05-15 2011-11-16 Immunonomedics, Inc. método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição
US20100163446A1 (en) 2006-06-28 2010-07-01 Fujimori Kogyo Co., Ltd. Liquid container
BRPI0622108A2 (pt) * 2006-10-18 2011-12-27 Tekni Plex Europ Nv mÉtodo de produÇço de uma pelÍcula com méltiplas camadas e pelÍcula produzida pelo referido mÉtodo
US7776022B2 (en) * 2007-03-19 2010-08-17 Hemcon Medical Technologies Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US20090223080A1 (en) * 2007-03-19 2009-09-10 Hemcon Medical Technologies, Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US20090036862A1 (en) * 2007-08-01 2009-02-05 Owens-Ilinois Healthcare Packaging Inc. Multilayer plastic container and method of storing lyophilized products
NZ560646A (en) * 2007-08-14 2010-01-29 Bomac Research Ltd Treatment apparatus
KR100847115B1 (ko) 2007-10-16 2008-07-18 센트럴메디컬서비스(주) 수액제 이중포장용기
US7918830B2 (en) * 2007-12-03 2011-04-05 Pharmedium Services, Llc Safety device for drug delivery devices and containers
ES2717616T3 (es) 2007-12-24 2019-06-24 Choongwae Corp Utilización de una película multicapa para recipiente de disolución médica y recipiente que comprende la misma
JP2011508634A (ja) * 2007-12-28 2011-03-17 アクティヴパック， インコーポレイテッド 患者への治療剤の投与に適したディスペンサおよび治療用パッケージ
BRPI0823117B8 (pt) 2008-09-29 2021-06-22 Vifor Int Ag receptáculo e método para armazenar e suprir um líquido e uma preparação médica líquida
US10118758B2 (en) * 2008-12-22 2018-11-06 Marat Purliyev Floatable infusion package

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1348898A (fr) * 1963-02-27 1964-01-10 Abbott Lab Sac pour contenir un liquide destiné à être administré à un patient
US4654240A (en) 1984-09-28 1987-03-31 Baxter Travenol Laboratories, Inc. Laminate film for flexible containers
WO1992019284A1 (en) * 1991-05-08 1992-11-12 Baxter International Inc. Container for irradiation of blood products
US5514106A (en) * 1994-12-20 1996-05-07 Baxter International Inc. Bag including an identification system indicative of treatment of the bag
WO1997042897A1 (en) * 1996-05-13 1997-11-20 B. Braun Medical Flexible, multiple-compartment drug container and method of making and using same
US5896989A (en) * 1998-02-20 1999-04-27 Bracco Research Usa Flexible medical container packaging
WO2002072429A1 (en) 2001-03-12 2002-09-19 Baxter International, Inc. Albumin in a flexible polymeric container
FR2824568A1 (fr) 2001-05-11 2002-11-15 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
FR2895263A1 (fr) 2005-12-26 2007-06-29 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
CN2882604Y (zh) * 2006-03-31 2007-03-28 湖南千山制药机械股份有限公司 带独立标签及装药接口的输液袋

Also Published As

Publication number Publication date
US20120145580A1 (en) 2012-06-14
BR112012004006A2 (pt) 2018-03-20
WO2011024112A1 (fr) 2011-03-03
KR20120048693A (ko) 2012-05-15
CN102548522A (zh) 2012-07-04
US9468585B2 (en) 2016-10-18
CA2771736A1 (fr) 2011-03-03
US20180049946A1 (en) 2018-02-22
IL218133A0 (en) 2012-06-28
PL2470147T3 (pl) 2016-03-31
ES2558529T3 (es) 2016-02-05
DK2470147T3 (da) 2016-01-25
EP2470147A1 (fr) 2012-07-04
US10342734B2 (en) 2019-07-09
FR2949195A1 (fr) 2011-02-25
FR2949195B1 (fr) 2011-10-14
AU2010288193A1 (en) 2012-03-08
EP2470147B1 (fr) 2015-10-14

Similar Documents

Publication Publication Date Title
EP2470147B1 (fr) Poche de stockage de solution therapeutique
AU2015380381B2 (en) Process for manufacturing glatiramer acetate product
KR101242905B1 (ko) 다수 챔버 용기
JP2002325823A (ja) 酸素感受性薬剤の一回服用量投薬
RU2381103C2 (ru) Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами
JP4607609B2 (ja) 薬液バッグ、薬液バッグ収容体および薬液バッグ収容体の製造方法
EP1799174B1 (fr) Ensemble de stockage pour produits de contraste.
CA2346564C (fr) Conditionnement d'une preparation d'oxaliplatine
WO2025146396A1 (en) Medicament bag
Sharma et al. Spotlight on Clinical In-Use Parameters for Intravenous Infusion of Therapeutic Antibodies: A Systematic Review
Legeron et al. Long-term physicochemical stability of acyclovir 5 mg/mL solution stored in polypropylene bags as a simulated hospital stock preparation
WO2019213268A1 (en) Ready-to-use liquid parenteral formulations of ribavirin
Rodríguez Trabado et al. A case of immediate hypersensitivity reaction to maltitol
CN102514755A (zh) 一种软袋包装的烟酸占替诺氯化钠注射液的制备方法
WO2025229465A1 (en) Multi-sealed packaging system and packaging material for products sensitive to environmental conditions
Airaudo et al. Comparative study of the sorption of clomipramine and viloxazine hydrochlorides in Stedim and PVC bags
WO2009094854A1 (en) Composite aluminum film outer package for medical infusion with non-pvc bag
HK1239526A1 (en) Prefilled syringe containing a glatiramer acetate product

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2470147

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17P Request for examination filed

Effective date: 20160929

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181025